Agios Pharmaceuticals (NASDAQ:AGIO) Shares Gap Down – What’s Next?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) gapped down before the market opened on Tuesday . The stock had previously closed at $33.97, but opened at $32.64. Agios Pharmaceuticals shares last traded at $33.53, with a volume of 27,907 shares trading hands.

Analyst Ratings Changes

Several equities research analysts have issued reports on AGIO shares. Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. Scotiabank lifted their price target on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a research note on Monday, December 9th. Royal Bank of Canada raised their price objective on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a report on Tuesday, December 10th. Finally, StockNews.com upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, November 9th. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $56.33.

Agios Pharmaceuticals Price Performance

The stock’s fifty day simple moving average is $37.33 and its 200-day simple moving average is $43.76. The stock has a market cap of $1.88 billion, a P/E ratio of 2.90 and a beta of 0.88.

Insider Activity at Agios Pharmaceuticals

In related news, insider Tsveta Milanova sold 2,804 shares of Agios Pharmaceuticals stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $32.18, for a total transaction of $90,232.72. Following the sale, the insider now directly owns 18,906 shares in the company, valued at $608,395.08. The trade was a 12.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 4.93% of the company’s stock.

Institutional Trading of Agios Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Venturi Wealth Management LLC acquired a new position in shares of Agios Pharmaceuticals during the fourth quarter valued at approximately $33,000. Wingate Wealth Advisors Inc. acquired a new position in shares of Agios Pharmaceuticals during the 4th quarter valued at $53,000. KBC Group NV raised its stake in shares of Agios Pharmaceuticals by 30.5% in the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company’s stock worth $86,000 after buying an additional 611 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Agios Pharmaceuticals by 21.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock valued at $94,000 after buying an additional 363 shares during the period. Finally, CWM LLC lifted its holdings in shares of Agios Pharmaceuticals by 554.7% in the third quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock valued at $96,000 after buying an additional 1,836 shares during the period.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.